Loading...

Biofactory

WSE:BFC
Snowflake Description

Solid track record and good value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BFC
WSE
PLN5M
Market Cap
  1. Home
  2. PL
  3. Materials
Company description

Biofactory S.A. produces and sells wooden products in Poland. The last earnings update was 77 days ago. More info.


Add to Portfolio Compare Print
  • Biofactory has significant price volatility in the past 3 months.
BFC Share Price and Events
7 Day Returns
0%
WSE:BFC
-0.4%
PL Forestry
-0.7%
PL Market
1 Year Returns
-
WSE:BFC
-32.3%
PL Forestry
-2.5%
PL Market
BFC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biofactory (BFC) 0% 0% -0.7% - -27.6% 13.1%
PL Forestry -0.4% 2.5% -18.8% -32.3% -21.8% -3.3%
PL Market -0.7% 0% 1.5% -2.5% 12.5% -3.5%
1 Year Return vs Industry and Market
  • No trading data on BFC.
  • No trading data on BFC.
Price Volatility
BFC
Industry
5yr Volatility vs Market

BFC Value

 Is Biofactory undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biofactory to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biofactory.

WSE:BFC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 17.1%
Perpetual Growth Rate 10-Year PL Government Bond Rate 2.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for WSE:BFC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year PL Govt Bond Rate 2.9%
Equity Risk Premium S&P Global 7.1%
Forestry Unlevered Beta Simply Wall St/ S&P Global 1.29
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.288 (1 + (1- 19%) (127.91%))
2.087
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.85% + (2 * 7.14%)
17.13%

Discounted Cash Flow Calculation for WSE:BFC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biofactory is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

WSE:BFC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (PLN, Millions) Source Present Value
Discounted (@ 17.13%)
2019 1.32 Est @ 3.72% 1.13
2020 1.37 Est @ 3.46% 1.00
2021 1.41 Est @ 3.28% 0.88
2022 1.46 Est @ 3.15% 0.77
2023 1.50 Est @ 3.06% 0.68
2024 1.54 Est @ 3% 0.60
2025 1.59 Est @ 2.95% 0.53
2026 1.64 Est @ 2.92% 0.46
2027 1.68 Est @ 2.9% 0.41
2028 1.73 Est @ 2.89% 0.36
Present value of next 10 years cash flows PLN6.80
WSE:BFC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= PLN1.73 × (1 + 2.85%) ÷ (17.13% – 2.85%)
PLN12.48
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= PLN12.48 ÷ (1 + 17.13%)10
PLN2.57
WSE:BFC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= PLN6.80 + PLN2.57
PLN9.37
Equity Value per Share
(PLN)
= Total value / Shares Outstanding
= PLN9.37 / 1.90
PLN4.93
WSE:BFC Discount to Share Price
Calculation Result
Value per share (PLN) From above. PLN4.93
Current discount Discount to share price of PLN2.68
= -1 x (PLN2.68 - PLN4.93) / PLN4.93
45.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Biofactory is available for.
Intrinsic value
46%
Share price is PLN2.68 vs Future cash flow value of PLN4.93
Current Discount Checks
For Biofactory to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Biofactory's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Biofactory's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biofactory's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biofactory's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
WSE:BFC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in PLN PLN0.27
WSE:BFC Share Price ** WSE (2019-03-29) in PLN PLN2.68
Poland Forestry Industry PE Ratio Median Figure of 8 Publicly-Listed Forestry Companies 20.63x
Poland Market PE Ratio Median Figure of 458 Publicly-Listed Companies 11.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biofactory.

WSE:BFC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= WSE:BFC Share Price ÷ EPS (both in PLN)

= 2.68 ÷ 0.27

9.78x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biofactory is good value based on earnings compared to the PL Forestry industry average.
  • Biofactory is good value based on earnings compared to the Poland market.
Price based on expected Growth
Does Biofactory's expected growth come at a high price?
Raw Data
WSE:BFC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 9.78x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
1.1%per year
Europe Forestry Industry PEG Ratio Median Figure of 21 Publicly-Listed Forestry Companies 1.09x
Poland Market PEG Ratio Median Figure of 114 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biofactory, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biofactory's assets?
Raw Data
WSE:BFC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in PLN PLN2.78
WSE:BFC Share Price * WSE (2019-03-29) in PLN PLN2.68
Poland Forestry Industry PB Ratio Median Figure of 8 Publicly-Listed Forestry Companies 0.69x
Poland Market PB Ratio Median Figure of 687 Publicly-Listed Companies 1x
WSE:BFC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= WSE:BFC Share Price ÷ Book Value per Share (both in PLN)

= 2.68 ÷ 2.78

0.96x

* Primary Listing of Biofactory.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biofactory is overvalued based on assets compared to the PL Forestry industry average.
X
Value checks
We assess Biofactory's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Forestry industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Forestry industry average (and greater than 0)? (1 check)
  5. Biofactory has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BFC Future Performance

 How is Biofactory expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Biofactory, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biofactory expected to grow at an attractive rate?
  • Biofactory's earnings growth is positive but not above the low risk savings rate of 2.9%.
Growth vs Market Checks
  • Biofactory's earnings growth is positive but not above the Poland market average.
  • Unable to compare Biofactory's revenue growth to the Poland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
WSE:BFC Future Growth Rates Data Sources
Data Point Source Value (per year)
WSE:BFC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 1.1%
Poland Forestry Industry Earnings Growth Rate Market Cap Weighted Average 41.7%
Europe Forestry Industry Revenue Growth Rate Market Cap Weighted Average 2%
Poland Market Earnings Growth Rate Market Cap Weighted Average 10.2%
Poland Market Revenue Growth Rate Market Cap Weighted Average 6.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
WSE:BFC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in PLN Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
WSE:BFC Past Financials Data
Date (Data in PLN Millions) Revenue Cash Flow Net Income *
2018-12-31 12 1 1
2018-09-30 12 1 1
2018-06-30 12 2 0
2018-03-31 13 1 0
2017-12-31 12 1 0
2017-09-30 12 1 0
2017-06-30 11 1 0
2017-03-31 11 1 0
2016-12-31 10 1 0
2016-09-30 10 1 0
2016-06-30 10 1 0
2016-03-31 10 1 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biofactory's earnings are expected to grow by 1.1% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if Biofactory is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
WSE:BFC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Biofactory Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:BFC Past Financials Data
Date (Data in PLN Millions) EPS *
2018-12-31 0.27
2018-09-30 0.29
2018-06-30 0.22
2018-03-31 0.20
2017-12-31 0.19
2017-09-30 0.16
2017-06-30 0.14
2017-03-31 0.14
2016-12-31 0.13
2016-09-30 0.12
2016-06-30 0.16
2016-03-31 0.17

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biofactory will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Biofactory's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Poland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biofactory has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BFC Past Performance

  How has Biofactory performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biofactory's growth in the last year to its industry (Forestry).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biofactory's year on year earnings growth rate has been positive over the past 5 years.
  • Biofactory's 1-year earnings growth exceeds its 5-year average (47.5% vs 9%)
  • Biofactory's earnings growth has exceeded the PL Forestry industry average in the past year (47.5% vs 19.6%).
Earnings and Revenue History
Biofactory's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biofactory Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

WSE:BFC Past Revenue, Cash Flow and Net Income Data
Date (Data in PLN Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 12.12 0.52 3.05
2018-09-30 12.21 0.55 3.02
2018-06-30 12.26 0.42 2.99
2018-03-31 12.57 0.38 2.98
2017-12-31 12.16 0.35 2.91
2017-09-30 11.53 0.30 2.87
2017-06-30 10.84 0.26 2.75
2017-03-31 10.64 0.26 2.75
2016-12-31 10.32 0.25 2.74
2016-09-30 10.36 0.23 2.73
2016-06-30 10.44 0.31 2.76
2016-03-31 9.57 0.32 2.60
2015-12-31 9.45 0.31 2.51
2015-09-30 9.25 0.27 2.44
2015-06-30 9.18 0.30 2.38
2015-03-31 9.68 0.30 2.43
2014-12-31 9.54 0.26 2.36
2014-09-30 9.00 0.35 2.32
2014-06-30 9.06 0.36 2.35
2014-03-31 8.95 0.39 2.34
2013-12-31 8.28 0.18 2.28
2013-09-30 8.27 0.28 2.14
2013-06-30 6.95 0.06 3.05
2013-03-31 6.22 -0.10 2.44
2012-12-31 6.61 0.03 1.97
2012-09-30 6.11 0.04 3.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Biofactory has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Biofactory used its assets more efficiently than the PL Forestry industry average last year based on Return on Assets.
  • Biofactory has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Biofactory's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Forestry industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biofactory has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BFC Health

 How is Biofactory's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biofactory's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biofactory is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biofactory's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Biofactory's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biofactory Company Filings, last reported 3 months ago.

WSE:BFC Past Debt and Equity Data
Date (Data in PLN Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 5.29 6.52 0.05
2018-09-30 5.23 6.83 0.06
2018-06-30 5.04 6.87 0.08
2018-03-31 5.09 7.02 0.02
2017-12-31 4.96 7.05 0.17
2017-09-30 4.87 7.01 0.26
2017-06-30 4.81 7.46 0.16
2017-03-31 4.82 7.64 0.10
2016-12-31 4.72 7.50 0.13
2016-09-30 4.69 7.12 0.20
2016-06-30 4.67 6.49 0.15
2016-03-31 4.56 5.87 0.02
2015-12-31 4.47 5.72 0.03
2015-09-30 4.47 5.71 0.09
2015-06-30 4.36 5.63 0.03
2015-03-31 4.24 5.01 0.02
2014-12-31 4.16 4.86 0.06
2014-09-30 4.20 5.08 0.04
2014-06-30 4.06 5.36 0.03
2014-03-31 3.94 5.20 0.01
2013-12-31 3.90 5.02 0.03
2013-09-30 3.85 5.36 0.09
2013-06-30
2013-03-31 3.72 4.64 0.00
2012-12-31 3.72 4.64 0.00
2012-09-30
  • Biofactory's level of debt (123.3%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (128.7% vs 123.3% today).
  • Debt is well covered by operating cash flow (22.8%, greater than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 2.9x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Biofactory's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biofactory has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BFC Dividends

 What is Biofactory's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
3.36%
Current annual income from Biofactory dividends.
If you bought PLN2,000 of Biofactory shares you are expected to receive PLN67 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Biofactory's pays a higher dividend yield than the bottom 25% of dividend payers in Poland (2.72%).
  • Biofactory's dividend is below the markets top 25% of dividend payers in Poland (7.69%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
WSE:BFC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Forestry Industry Average Dividend Yield Market Cap Weighted Average of 22 Stocks 4.2%
Poland Market Average Dividend Yield Market Cap Weighted Average of 207 Stocks 3.2%
Poland Minimum Threshold Dividend Yield 10th Percentile 1.4%
Poland Bottom 25% Dividend Yield 25th Percentile 2.7%
Poland Top 25% Dividend Yield 75th Percentile 7.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

WSE:BFC Past Annualized Dividends Data
Date (Data in PLN) Dividend per share (annual) Avg. Yield (%)
2018-04-30 0.090 3.146
2018-01-31 0.090 2.952
2017-05-02 0.060 1.923
2017-01-31 0.060 1.748

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Biofactory has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Biofactory only paid a dividend in the past 2 years.
Current Payout to shareholders
What portion of Biofactory's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biofactory's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biofactory afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biofactory has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BFC Management

 What is the CEO of Biofactory's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Krzysztof Trochim
TENURE AS CEO 7 years
CEO Bio

Mr. Krzysztof Trochim has been President of the Management Board and Member of The Management Board of Biofactory S.A. since April 10, 2012. Mr. Trochim served as Chairman of the Board at Biofactory S.A.

CEO Compensation
  • Insufficient data for Krzysztof to compare compensation growth.
  • Insufficient data for Krzysztof to establish whether their remuneration is reasonable compared to companies of similar size in Poland.
Management Team

Krzysztof Trochim

TITLE
President of the Management Board
TENURE
7 yrs

Agnieszka Pyzik

TITLE
Chief Accountant

Krzysztof Olbrycht

TITLE
Secretary of the Supervisory Board
Board of Directors

Kazimierz Szot

TITLE
Chairman of the Supervisory Board

Zbigniew Lipieta

TITLE
Vice Chairman of the Supervisory Board

Dariusz Kurpiewski

TITLE
Member of the Supervisory Board

Tomasz Sierakowski

TITLE
Member of the Supervisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (PLN) Value (PLN)
X
Management checks
We assess Biofactory's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biofactory has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BFC News

Simply Wall St News

These Fundamentals Make Biofactory S.A. (WSE:BFC) Truly Worth Looking At

(WSE:BFC) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … trading at a great value

Simply Wall St -

Biofactory S.A.'s (WSE:BFC) Earnings Grew 48%, Did It Beat Long-Term Trend?

(WSE:BFC) released its most recent earnings update (31 December 2018), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … BFC's trailing twelve-month earnings (from 31 December 2018) of zł521k has. … Furthermore, this one-year growth rate has exceeded its 5-year annual growth average of 9.0%, indicating the rate at which BFC is growing has accelerated

Simply Wall St -

Introducing Biofactory, The Stock That Dropped 33% In The Last Three Years

(WSE:BFC) shareholders, since the share price is down 33% in the last three years, falling well short of the market return of around 27%. … One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … During the unfortunate three years of share price decline, Biofactory actually saw its earnings per share (EPS) improve by 19% per year.

Simply Wall St -

What You Must Know About Biofactory S.A.'s (WSE:BFC) Financial Strength

Help shape the future of investing tools and you could win a $250 gift card! … (WSE:BFC) with its market cap of zł5.1m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Should You Worry About Biofactory S.A.’s (WSE:BFC) ROCE?

In particular, we'll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business. … Return On Capital Employed (ROCE): What is it? … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.

Simply Wall St -

Does Biofactory S.A. (WSE:BFC) Have A Place In Your Dividend Stock Portfolio?

(WSE:BFC) has paid a dividend to shareholders in the last few years. … Does Biofactory tick all the boxes of a great dividend stock? … How I analyze a dividend stock

Simply Wall St -

Here's What Biofactory SA's (WSE:BFC) P/E Ratio Is Telling Us

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … That is equivalent to an earnings yield of about 10%. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

How Good Is Biofactory SA (WSE:BFC), When It Comes To ROE?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows Biofactory has a return on equity of 8.3% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

How Financially Strong Is Biofactory SA (WSE:BFC)?

While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … So, understanding the company's financial health becomes. … Here are few basic financial health checks you should consider before taking the plunge.

Simply Wall St -

Is Biofactory SA (WSE:BFC) A Strong Dividend Stock?

Biofactory SA (WSE:BFC) has returned to shareholders over the past 2 years, an average dividend yield of 2.00% annually. … Does Biofactory tick all the boxes of a great dividend stock? … 5 checks you should use to assess a dividend stock

Simply Wall St -

BFC Company Info

Description

Biofactory S.A. produces and sells wooden products in Poland. The company offers softwood timber, crop and unsolved beam, oak saw, elements of wood, trocine, and fireplace wood products. It also provides wood wiping, steaming lumber and leafy frieze, drying lumber and frieze, and submerged impregnation services. The company also exports its products to Slovakia, Hungary, Germany, Austria, and Sweden. Biofactory S.A. was founded in 1919 and is headquartered in Biecz, Poland.

Details
Name: Biofactory S.A.
BFC
Exchange: WSE
Founded: 1919
PLN5,097,360
1,902,000
Website: http://www.biofactory.pl
Address: Biofactory S.A.
ul. Kazimierz Wielki 21,
Biecz,
38-340,
Poland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
WSE BFC Bearer Shares Warsaw Stock Exchange PL PLN 19. Sep 2012
Number of employees
Current staff
Staff numbers
0
Biofactory employees.
Industry
Forest Products
Materials
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:53
End of day share price update: 2019/03/29 00:00
Last earnings filing: 2019/01/31
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.